Premium
Update on clinical evidence (Part II): A summary of the main post market studies
Author(s) -
Tamburino Corrado,
Capranzano Piera,
Francaviglia Bruno,
Ina Tamburino Claudia,
Longo Giovanni,
Capodanno Davide
Publication year - 2016
Publication title -
catheterization and cardiovascular interventions
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.988
H-Index - 116
eISSN - 1522-726X
pISSN - 1522-1946
DOI - 10.1002/ccd.26809
Subject(s) - medicine , medline , intensive care medicine , medical physics , law , political science
Bioresorbable vascular scaffolds (BVS, Absorb, Abbott Vascular, Santa Clara, CA) received the CE mark in October 2011, and were approved by the Food and Drug Administration in July 2016. After their introduction in clinical practice a broad amount of post‐marketing clinical experience with BVS has been generated so far in Europe and outside the United States. The available BVS registries differ in many aspects, including their being single‐center or multicenter, single‐arm or controlled, sponsored or investigator‐initiated, published or presented at a large‐scale international meeting. This article provides an overview of clinical results of the main post‐marketing studies of BVS available. © 2016 Wiley Periodicals, Inc.